Lyme Policy Wonk: Beam me up, Scotty. See you after the jump!

Byldoadmin

I spoke at the annual patient advocacy training session.  The theme of my talk was from a book on social activism by Bill Moyer entitled “Doing Democracy”.  I spoke before a group that understand the importance of the work we are doing.  How lucky is that?  A group of people trying to make a difference.  The Lyme community has more activists per square mile than any other illness.  Is it any wonder? 

My talk focused in on another group that had gone through a similar struggle—breast cancer.  I was astonished at the overlay of Lyme and breast cancer.  Did you know that women with breast cancer passed laws in 17 states (really!) to secure the right to a lumpectomy against an entrenched medical establishment that did not understand why patients should have any say in treatment.  Now think about that.  And then think about how a lumpectomy is not controversial anymore.  Not at all.  That is a  future worth creating.  I hope to see you after that jump.  Beam me up, Scotty!

 

Similar Posts

  • LYMEPOLICYWONK: New Lyme Disease Culture Test Could be Game Changer

    Advanced Laboratory Services Inc. (ALSI) has announced a new culture test for Lyme disease. It is commercially available in all states except California, New York and Florida, which have individual state licensing requirements that must be met before the test can be offered. Direct detection of bacteria through culture is considered the “gold standard” for diagnosis, but this method has not been commercially available for Lyme disease using previous culture methods. The new test is based on research conducted by Dr. Eva Sapi and colleagues, which CALDA helped fund. Results of the research published earlier this year demonstrated the improved culture method for Borrelia burgdorferi, the agent of Lyme disease, and the technique has recently been corroborated using human blood samples. Larger confirmatory studies of the test are now being pursued. Dr. Joseph Burrascano, a pioneer in the treatment of Lyme disease, consulted with ALSI to help make the test commercially available. A sensitive high-quality culture test would not only permit patients to be accurately diagnosed, but would lay to rest much of the controversy surrounding Lyme disease.

  • LYMEPOLICYWONK: Patient-Centered Medicine and Lyme disease.

    We are in the midst of a sea of change in healthcare—driven largely by healthcare reform and evidence based medicine. Public trust is critical to the success of healthcare reform. But many patients believe that EBM is vulnerable to corruption by stakeholders—like insurers seeking to control costs and panel members who have industry conflicts of interest. Patient distrust in IDSA Lyme guidelines is high because Lyme patients believe that the guidelines panel was corrupted by industry conflicts (diagnostic tests, vaccines, and insurance) and researcher self-interest. Today, a shift from old models of medicine toward patient-centered medicine is emerging. It seeks to focus medical attention on the individual patient needs and concerns rather than those of physicians, insurers, pharmaceutical companies, and researchers. At LymeDisease.org we have been up to our eye-balls in EBM and patient-centered care since 2004, when we launched the two standards of care campaign.

  • LYMEPOLICYWONK: Institute of Medicine Cuts on the Bias for IDSA

    Finally, the Institute of Medicine (IOM) came out with its agenda for their “State of the Science Hearing”after much hemming and hawing. Patient groups (including CALDA) who asked for transparency in the study process received a mere “no comment” response. Well, we never got transparency, and we only got the agenda after it was finalized and released to the public. So, here’s the score: its 3 for 3 in the ‘Final Inning’ in favor of the IDSA.

    Four of the 6 IOM panel members are IDSA members.

    10 of the 14 physician speakers were authors on the IDSA guidelines or the copycat guidelines issued by members of the IDSA panel or members of the IDSA.

    Zero ILADS physicians have been chosen to speak. Let me repeat: ZERO, zip, nada, not a single ILADS physician was chosen to speak!

    Dr. Gary Wormser, poster boy of the Connecticut IDSA antitrust investigation, is kicking off the game.

    Oh, there’s window dressing to be sure. A personalized tour of the Agenda after the great leap forward. . .

  • IDSA Virtual Lobby Now Open – VIEW LIVE WEBCAST

    The IDSA Virtual Lobby is now open (see link below). In addition, the IDSA has posted a terms of use on the virtual lobby–these terms are the IDSA's one-sided view of how copyright restrictions etc should play out. You do not need to read the terms before viewing the presentations and you SHOULD NOT. The IDSA is not entitled to post any restrictions on viewing, period, beginning and end of story. I would not want to give them any argument that people read their terms before viewing and the best way to ensure that is to simply not view the terms before viewing.

  • |

    LYMEPOLICYWONK: Lyme Disease: Call for a “Manhattan Project” to Combat the Epidemic

    PLOS Pathogens just published the most recent commentary by Dr. Stricker and me on Lyme disease calling for a Manhattan Project effort to seriously tackle this debilitating illness in light of the CDC’s increase in annual incidence from 30,000 to 300,000. An excerpt and a link to the full article, which is available open access is below.